导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 4.57% | 1376/4773 |
| 近一周 | -4.35% | 5097/5465 |
| 近一月 | -0.90% | 968/5421 |
| 近一季 | -6.62% | 2475/5231 |
| 近半年 | -12.89% | 3839/4920 |
| 近一年 | 18.10% | 658/4394 |
| 近两年 | 79.57% | 853/2954 |
| 近三年 | 49.35% | 568/2253 |
| 成立以来 | 205.00% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
10.95% 47/4961 |
-4.10% 3488/5312 |
- - |
- - |
| 2025 | 44.29% 632/4813 |
2.42% 1378/3635 |
2.11% 1862/4076 |
25.50% 1394/4524 |
9.95% 185/4813 |
| 2024 | 4.34% 1881/3463 |
4.22% 470/2808 |
-3.56% 1389/3014 |
10.18% 2644/3129 |
-5.78% 2590/3463 |
| 2023 | -3.13% 626/2656 |
4.94% 852/2280 |
-6.66% 1684/2385 |
2.35% 238/2515 |
-3.37% 669/2655 |
| 2022 | -9.55% 178/2207 |
-3.58% 158/1919 |
3.05% 1224/2016 |
-8.02% 161/2113 |
-1.04% 1671/2208 |
| 2021 | 43.14% 19/1822 |
6.00% 103/1255 |
11.54% 370/1330 |
27.48% 16/1466 |
-5.04% 1502/1822 |
| 2020 | 23.89% 643/1250 |
-8.99% 646/1028 |
5.28% 888/1067 |
11.92% 414/1164 |
15.53% 202/1184 |
| 2019 | 26.54% 572/1092 |
28.91% 289/754 |
-3.37% 392/804 |
-5.22% 787/850 |
7.18% 474/918 |
| 2018 | -36.50% 590/834 |
- - |
- - |
- - |
-13.29% 525/691 |
| 2017 | 12.38% 281/714 |
- - |
- - |
- - |
- - |
| 2016 | -0.87% 113/605 |
- - |
- - |
- - |
- - |
| 2015 | 20.89% 112/575 |
- - |
- - |
- - |
- - |
| 2014 | 25.78% 181/237 |
- - |
- - |
- - |
- - |
| 2013 | -20.23% 174/186 |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 招商大宗商品(LOF) VS. 长安沪深300非周期A(740101) |